Johnson & Johnson COVID-19 Vaccine Receives FDA Approval



Johnson & Johnson has received an Emergency Use Authorization for its vaccine in the United States, offering single-dose benefits and standard storage requirements.

Johnson & Johnson (JNJ) received FDA clearance on Saturday for emergency use of its COVID-19 vaccine in the country.

Johnson & Johnson, which has gained nearly 14% in the past 12 months, surged 3.52% before trading opened on Monday.

J&J previously said it plans to deliver 20 million doses of its vaccine by the end of March from a government contract to supply 100 million doses by the end of June.

Although Pfizer (PFE) and BioNTech (BNTX), as well as Moderna (MRNA), have outpaced J&J in starting supplies of vaccines against coronavirus, the J&J vaccine has an advantage over them, as it creates high immunity against coronavirus with a single injection, without requiring re-vaccination.

J&J vaccine does not require special storage conditions and can be stored at 2.2 ℃ – 7.8 ℃, unlike Pfizer and BioNTech vaccines, which require very low temperatures.

The protection rate of J&J vaccine varied by region, with an average efficacy of 66%, with 72% efficacy among those tested in the US, 66% in Latin America, and 57% in South Africa. However, after about a month, the vaccine’s effectiveness in South Africa had grown to 64%.

According to a J&J press release, its vaccine has proven effective against a new, more infectious strain of the SARS-CoV-2 B.1.351 coronavirus spread in South Africa.

Pfizer and Moderna vaccines were 95% and 94% effective, respectively, but the data did not include testing for new strains of coronavirus. These companies are currently conducting additional research.

The J&J vaccine prevented 100% of hospitalizations and deaths among 43,783 test participants aged 18 and over, and met the FDA’s minimum vaccine requirement of 50%, the company said.

Johnson & Johnson executives previously said the company would not make money from vaccines during the pandemic, but would be provided “on a non-profit basis for emergency use.”

J&J could profit from COVID-19 vaccines if such vaccinations are included in the calendar of annual mandatory vaccinations in the United States and other countries.

Libertex [CPS] WW

xemarketsforex

xemarketsforex

MTP Procurement Management Procurement Bidding SRM Cost Optimization Team Management Cost Management SAP ERP Management Skills SAP ERP 1C Supply Control SAP / SRM SAP / R3 Analytical Thinking Working with Suppliers Result Oriented System Thinking Process Management Strategic Planning Project Management MsOffice Negotiations with company top officials Organization of procurement procedures Oil trading

Read Previous

Review of the dollar, euro, pound, yen, qiwi and gold prices for March 1, 2021

Read Next

More and more Russians feel the negative effect of the pandemic on their incomes